細胞番号 : 細胞名 RCB2093 : II-18  update : 2024/08/14
細胞特性(Comment:英)			Human cell line derived from lung cancer. Adenocarcinoma. TKG0177 (Deposited from Tohoku Univ.).
細胞特性(日)			ヒト肺癌由来細胞株。Adenocarcinoma. TKG0177 (東北大学医用細胞資源センターからの寄託)。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)			A prior written permission of the approver(Originator) is necessary for any kind of use including academic use and for-profit use.
使用条件(日)			営利目的か非営利目的かを問わず、いかなる使用につきましても、承諾者(樹立者)から承諾を得ることが必要です。
備考(英)
備考(日)
承諾者住所			× Japanese 住所 989-3203 宮城県仙台市青葉区中山吉成2-3-1 公益財団法人宮城県結核予防会   小林 俊介 先生 Fax. 022-719-5166 English Address Japan Anti-Tuberculosis Association MIYAGI 2-3-1 Nakayamayoshinari, Aoba-ku, Sendai, Miyagi 989-3203 Japan Dr. KOBAYASHI Syunsuke Fax. +81-22-719-5166
提供申込書類(英)			Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日)			依頼書C-0001.pdf   承諾書C-0002.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf
			提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料			手数料とお支払いについてはこちらをご覧ください。
細胞基本情報		寄託者	Obinata, Masuo
		樹立者	Kobayashi, Syunsuke
		寄託日	2005
		元の細胞	TKG0177
		動物種	_human < Mammals
		属名	homo
		種名	sapiens
		採取組織	lung
		病名	adenocarcinoma
		細胞分類	cancer
		入手歴	Cell Resource Center for Biomedical Research, Tohoku University（TKG0177）
		細胞寿命	infinite
		細胞形態	epithelial-like
		Cellosaurus(Expasy)	CVCL_6659
細胞培養・検査情報			寄託時情報	ロット情報
	培地・試薬情報		培地・試薬一覧はこちらをご覧ください。
		培養形態		Adherent cells
		培地		RPMI1640 + 10% FBS
		抗生物質		Free
		継代方法		0.25% Trypsin
		継代密度		1 : 8 split
		継代・培地交換頻度		Subculture : once/week, Medium Renewal : 2 times/week
		培養最適温度		37 ℃
		二酸化炭素濃度		5 %
		凍結培地		Medium + 10% DMSO
		凍結方法		Slow freezing
		マイコプラズマ/アコレプラズマ		(-)
		アイソザイム検査		LD, NP
		個体識別検査		OK
画像情報			寄託時情報	ロット情報
文献情報		Reference(英)	1件
		Reference(日)	0件
		利用者成果(英)	23件
		利用者成果(日)	0件

ページトップへ

Reference(英)

3447      Kokenshi  1990  42:73-79

ページトップへ

Reference(日)

ページトップへ

利用者成果(英)

21631  Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K, Okamoto I.  TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.  NPJ Precis Oncol  2024  8(1):60  PubMed ID: 38431700   DOI: 10.1038/s41698-024-00557-2

22524  Kasai F, Fukushima M, Miyagi Y, Nakamura Y.  Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan  Hum Cell  2024  37(4):944-950  PubMed ID: 38639832   DOI: 10.1007/s13577-024-01055-0

19849  Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, Ishii Y, Ota K, Yoneshima Y, Iwama E, Okamoto I.  Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β  Front Immunol  2023  14:1192861  PubMed ID: 37441079   DOI: 10.3389/fimmu.2023.1192861

21042  Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, Inoue H, Tanaka K, Nakanishi Y, Okamoto I.  Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.  Lung Cancer  2023  175:101-111  PubMed ID: 36495783   DOI: 10.1016/j.lungcan.2022.11.018

21347  Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y.  L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.  Cell Rep Med  2023  101142  PubMed ID: 37557179   DOI: 10.1016/j.xcrm.2023.101142

21446  Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, Okamoto I.  YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells.  Biochem Biophys Res Commun  2023  681:120-126  PubMed ID: 37774569   DOI: 10.1016/j.bbrc.2023.09.067

20501  Yasuda Y, Nagano T, Jimbo N, Kiriu T, Suraya R, Hazama D, Yamamoto M, Maniwa Y, Nishimura Y, Kobayashi K.  Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma.  Anticancer Res  2022  42(1):271-277  PubMed ID: 34969734   DOI: 10.21873/anticanres.15482

22528  Kooijman JJ, van Riel WE, Dylus J, Prinsen MBW, Grobben Y, de Bitter TJJ, van Doornmalen AM, Melis JJTM, Uitdehaag JCM, Narumi Y, Kawase Y, de Roos JADM, Willemsen-Seegers N, Zaman GJR.  Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020  Front Oncol  2022  12:953013  PubMed ID: 36185300   DOI: 10.3389/fonc.2022.953013

18209  Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, Eli LD, Lalani AS, Crown J, Collins DM.  Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors  Br J Cancer  2021  124(7):1249-1259  PubMed ID: 33473169   DOI: 10.1038/s41416-020-01257-x

20304  Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K.  Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.  Lung Cancer  2021  158:115-125  PubMed ID: 34157583   DOI: 10.1016/j.lungcan.2021.06.011

13215  Miwa N, Nagano T, Jimbo N, Dokuni R, Kiriu T, Mimura C, Yasuda Y, Katsurada M, Yamamoto M, Tachihara M, Tanaka Y, Kobayashi K, Itoh T, Maniwa Y, Nishimura Y.  Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma.  Onco Targets Ther  2020    PubMed ID: 32982291   DOI: 10.2147/OTT.S265539

14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677   DOI: 10.1007/s00705-019-04474-9

4872  Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.  Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.  Mol Cancer Ther  2019  18(8):1366-1373  PubMed ID: 31092564   DOI: 10.1158/1535-7163.MCT-18-0976

11040  Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura   Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion  BMC Cancer  2019  19(1):301  PubMed ID: 30943926   DOI: 10.1186/s12885-019-5527-2

10768  Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.  Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.  Sci Rep  2018  8:3482  PubMed ID: 29472726   DOI: 10.1038/s41598-018-21161-y

10411  Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S, Tamura D, Yamamoto M, Tachihara M, Kobayashi K, Satouchi M, Nishimura Y.  Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.  Cancer Sci.  2017  108:1368-1377  PubMed ID: 28445002   DOI: 10.1111/cas.13266

19389  Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E.  Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells  Cancer Immunol Res  2016  4(12):1049-1060  PubMed ID: 27799141   DOI: 10.1158/2326-6066.CIR-15-0266

12672  Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.  Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors  Oncologist  2016  21(2):156-64  PubMed ID: 26768482   DOI: 10.1634/theoncologist.2015-0288

14941  Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T.  A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer  Int J Oncol  2015  46(2):497-504  PubMed ID: 25532027   DOI: 10.3892/ijo.2014.2787

16538  Shimomura M, Yaoi T, Itoh K, Kato D, Terauchi K, Shimada J, Fushiki S.  Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines  Int J Oncol  2012  40(4):995-1004  PubMed ID: 22179563   DOI: 10.3892/ijo.2011.1297

8277  Shirogane Y, Takeda M, Tahara M, Ikegame S, Nakamura T, Yanagi Y.  Epithelial-mesenchymal transition abolishes the susceptibility of polarized epithelial cell lines to measles virus.  J. Biol. Chem.  2010  285:20882-90  PubMed ID: 20435897   DOI: 10.1074/jbc.M110.102590

6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x

18309  Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S.  Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth  Cancer Res  2008  68(5):1303-9  PubMed ID: 18316592   DOI: 10.1158/0008-5472.CAN-07-5003

ページトップへ

利用者成果(日)